Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
October 6, 2021 11:16 AM EDTUpdated 04:41 PM
Pharma

A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

Kyle Blankenship

Gink­go Bioworks, a syn­thet­ic bi­ol­o­gy uni­corn that has cap­tured in­vestors’ imag­i­na­tions and trades un­der Genen­tech’s hal­lowed old $DNA tick­er, took a big blow Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times